Colistin-sparing regimens against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates: Combination of tigecycline or doxycycline and gentamicin or amikacin

Journal of Microbiology, Immunology and Infection

Volumn 52, Issue 2, 2019, Pages 273-281

  Tang, Hung Jen ^a,b   Lai, Chih Cheng ^a   Chen, Chi Chung ^a,c   Zhang, Chun Cheng ^a   Weng, Tzu Chieh ^a   Chiu, Yu Hsin ^a   Toh, Han Siong ^a   Chiang, Shyh Ren ^a   Yu, Wen Liang ^a   Ko, Wen Chien ^c   Chuang, Yin Ching ^a  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

aminoglycoside; doxycycline; KPC; synergism; tigecycline

Indexed keywords

AMIKACIN; DOXYCYCLINE; GENTAMICIN; TIGECYCLINE; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; BACTERIAL DNA; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEMASE; COLISTIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CONTROLLED STUDY; DRUG POTENTIATION; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; BIOSYNTHESIS; DRUG COMBINATION; DRUG EFFECT; ENZYMOLOGY; GENETICS; GENOTYPE; HUMAN; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE;

AMIKACIN; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; COLISTIN; DNA, BACTERIAL; DOXYCYCLINE; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; GENOTYPE; GENTAMICINS; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; TIGECYCLINE;

EID: 85019378081     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2016.03.003     Document Type: Article

References (38)

1. Liu, S.W., Chang, H.J., Chia, J.H., Kuo, A.J., Wu, T.L., Lee, M.H., Outcomes and characteristics of ertapenem-nonsusceptible Klebsiella pneumoniae bacteremia at a university hospital in Northern Taiwan: a matched case-control study. J Microbiol Immunol Infect 45 (2012), 113–119.
2. Nordmann, P., Naas, T., Poirel, L., Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17 (2011), 1791–1798.
3. Hung, K.H., Yan, J.J., Lu, J.J., Chen, H.M., Wu, J.J., Characterization of the modified Hodge test-positive isolates of Enterobacteriaceae in Taiwan. J Microbiol Immunol Infect 46 (2013), 35–40.
4. Jean, S.S., Lee, W.S., Hsueh, P.R., Nationwide spread of Klebsiella pneumoniae carbapenemase-2-producing K. pneumoniae sequence type 11 in Taiwan. J Microbiol Immunol Infect 46 (2013), 317–319.
5. Chiu, S.K., Wu, T.L., Chuang, Y.C., Lin, J.C., Fung, C.P., Lu, P.L., et al. National surveillance study on carbapenem non-susceptible Klebsiella pneumoniae in Taiwan: the emergence and rapid dissemination of KPC-2 carbapenemase. PLoS ONE, 8, 2013, e69428.
6. Chen, Y.T., Lin, J.C., Fung, C.P., Lu, P.L., Chuang, Y.C., Wu, T.L., et al. KPC-2-encoding plasmids from Escherichia coli and Klebsiella pneumoniae in Taiwan. J Antimicrob Chemother 69 (2014), 628–631.
7. Zavascki, A.P., Barth, A.L., Gaspareto, P.B., Goncalves, A.L., Moro, A.L., Fernandes, J.F., et al. Risk factors for nosocomial infections due to Pseudomonas aeruginosa producing metallo-beta-lactamase in two tertiary-care teaching hospitals. J Antimicrob Chemother 58 (2006), 882–885.
8. Jean, S.S., Lee, W.S., Lam, C., Hsu, C.W., Chen, R.J., Hsueh, P.R., Carbapenemase-producing Gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options. Future Microbiol 10 (2015), 407–425.
9. Kanj, S.S., Kanafani, Z.A., Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 86 (2011), 250–259.
10. Livermore, D.M., Warner, M., Mushtaq, S., Doumith, M., Zhang, J., Woodford, N., What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 37 (2011), 415–419.
11. Tumbarello, M., Viale, P., Viscoli, C., Trecarichi, E.M., Tumietto, F., Marchese, A., et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 55 (2012), 943–950.
12. Jernigan, M.G., Press, E.G., Nguyen, M.H., Clancy, C.J., Shields, R.K., The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 56 (2012), 3395–3398.
13. Agwuh, K.N., MacGowan, A., Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 58 (2006), 256–265.
14. Elemam, A., Rahimian, J., Doymaz, M., In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. J Clin Microbiol 48 (2010), 3558–3562.
15. Farago, E., Kiss, J., Gomory, A., Aranyosi, J., Juhasz, I., Mihoczy, L., Amikacin: in vitro bacteriological studies, levels in human serum, lung and heart tissue, and clinical results. Int J Clin Pharmacol Biopharm 17 (1979), 421–428.
16. Tayman, C., El-Attug, M.N., Adams, E., Van Schepdael, A., Debeer, A., Allegaert, K., et al. Quantification of amikacin in bronchial epithelial lining fluid in neonates. Antimicrob Agents Chemother 55 (2011), 3990–3993.
17. Saux, M.C., Crockett, R., Fourtillan, J.B., Leng, B., Couraud, L., Diffusion of amikacin in the lungs. Pathol Biol (Paris) 34 (1986), 113–117.
18. Hirsch, E.B., Guo, B., Chang, K.T., Cao, H., Ledesma, K.R., Singh, M., et al. Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. J Infect Dis 207 (2013), 786–793.
19. Sbrana, F., Malacarne, P., Viaggi, B., Costanzo, S., Leonetti, P., Leonildi, A., et al. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit. Clin Infect Dis 56 (2013), 697–700.
20. Hirsch, E.B., Tam, V.H., Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 65 (2010), 1119–1125.
21. Ma, L., Siu, L.K., Lin, J.C., Wu, T.L., Fung, C.P., Wang, J.T., et al. Updated molecular epidemiology of carbapenem-non-susceptible Escherichia coli in Taiwan: first identification of KPC-2 or NDM-1-producing E. coli in Taiwan. BMC Infect Dis, 13, 2013, 599.
22. Clinical and Laboratory Standards Institute (CLSI), Performance standards for antimicrobial susceptibility testing: 16th informational supplement. Document M100–S22. 2012, CLSI, Wayne, PA.
23. Brown, S.D., Traczewski, M.M., Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control. J Clin Microbiol 45 (2007), 2173–2179.
24. Clinical and Laboratory Standards Institute (CLSI), Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically—8th Edition. Approved Standard M07–A9. 2009, CLSI, Wayne, PA.
25. Tenover, F.C., Arbeit, R.D., Goering, R.V., Mickelsen, P.A., Murray, B.E., Persing, D.H., et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33 (1995), 2233–2239.
26. National Committee for Clinical Laboratory Standards, Methods for determining bactericidal activity of antimicrobial agents: approved guideline. Document M26-A. 1999, CLSI, Wayne, PA.
27. Eliopoulos, G.M., Moellering, R.C. Jr., Antibiotics in laboratory medicine. Lorian, V., (eds.) Antimicrobial combinations, 4th ed., 1996, The Williams & Wilkins Co., Baltimore, MD, 330–396.
28. Moody, J.A., Synergy testing: broth microdilution checkerboard and broth macrodilution methods. Eisenberg, H.D., (eds.) Clinical microbiology procedures handbook, 1992, American Society for Microbiology, Washington, D.C. 5.18.1–23.
29. White, R.L., Burgess, D.S., Manduru, M., Bosso, J.A., Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother 40 (1996), 1914–1918.
30. Alrabaa, S.F., Nguyen, P., Sanderson, R., Baluch, A., Sandin, R.L., Kelker, D., et al. Early identification and control of carbapenemase-producing Klebsiella pneumoniae, originating from contaminated endoscopic equipment. Am J Infect Control 41 (2013), 562–564.
31. Qureshi, Z.A., Paterson, D.L., Potoski, B.A., Kilayko, M.C., Sandovsky, G., Sordillo, E., et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56 (2012), 2108–2113.
32. Daikos, G.L., Markogiannakis, A., Souli, M., Tzouvelekis, L.S., Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective. Expert Rev Anti Infect Ther 10 (2012), 1393–1404.
33. Nordmann, P., Cuzon, G., Naas, T., The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 9 (2009), 228–236.
34. Meagher, A.K., Ambrose, P.G., Grasela, T.H., Ellis-Grosse, E.J., Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 52 (2005), 165–171.
35. Rodriguez-Hernandez, M.J., Pachon, J., Pichardo, C., Cuberos, L., Ibanez-Martinez, J., Garcia-Curiel, A., et al. Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J Antimicrob Chemother 45 (2000), 493–501.
36. Goel, N., Chaudhary, U., Aggarwal, R., Bala, K., Antibiotic sensitivity pattern of gram negative bacilli isolated from the lower respiratory tract of ventilated patients in the Intensive care unit. Indian J Crit Care Med 13 (2009), 148–151.
37. Cunha, B.A., Sibley, C.M., Ristuccia, A.M., Doxycycline. Ther Drug Monit 4 (1982), 115–135.
38. Selvadurai, M., Meyyanathan, S.N., Rajan, S., Padmanaban, G., Suresh, B., Determination of doxycycline in human plasma by liquid chromatography-mass spectrometry after liquid-liquid extraction and its application in human pharmacokinetics studies. J Bioequiv Availab 2 (2010), 93–97.